Parkinson’s disease may be helped by GLP-1 drug, new study finds. By Elaine Chen April 3, 2024. Reprints. Adobe. T he booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only ...

The glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Adlyxin) led to less progression of motor disability compared with placebo in early Parkinson's disease, the phase II LIXIPARK ...

GLP-1s are being studied for cardiovascular disease, liver conditions, kidney disease, and Alzheimer’s. Older approved GLP-1s from Novo Nordisk, Sanofi, and Amylin have been or are being ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

For adults with T2D and obesity, GLP-1 RAs are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers.

Q: I have Parkinson's disease. I was diagnosed 10 months ago, and it is already affecting my ability to walk and to use my hands. My husband recently read that there's a diabetes drug that can slo ...

"One strategy to move forward with GLP-1 agonists could be to better select the participants with Parkinson's disease -- e.g., young people with high inflammatory activity who would benefit most ...

Parkinson’s disease (PD), the second most prevalent neurodegenerative disorder worldwide, is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, leading to a ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson’s disease. The 96-week trial, published in The ...

Barclays cites implications for the biopharma sector after a mid-stage trial showed that the GLP-1 agonist lixisenatide benefited Parkinson's patients. Read more here.

Dear Doctors: I have Parkinson’s disease. ... This is a class of drug known as glucagon-like peptide-1 (GLP-1) and is similar to Ozempic. The other participants were given a placebo.